Inventaire - els teus amics i comunitats són la teva millor biblioteca

Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial

autor

Anna Goussia

Nafsika Simou

Christos Markopoulos

Charisios Karanikiotis

publicat a: PLOS One

date of publication: 2018-07-31

tema principal: angiogènesi

Cites articles 46

Date

Títol

Autors

2016-05-19

Predictive role of the overexpression for CXCR4, C-Met, and VEGF-C among breast cancer patients: A meta-analysis
2016-10

Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer

Domenico Ribatti
2016-11-03

Prognostic Significance of High VEGF-C Expression for Patients with Breast Cancer: An Update Meta Analysis

Zhiqiao Zhang
2015-03-25

Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) study

Mattheos Bobos, George Fountzilas, Vassiliki Kotoula, Dimitrios Pectasides, Angelos Koutras, Dimitrios Bafaloukos, Dimosthenis Skarlos, Sofia Chrisafi, Pavlos Papakostas, Gerasimos Aravantinos, Zoi Alexopoulou, Flora Zagouri, Irene Papaspirou, Ioannis Efstratiou
2015-04-23

Defining breast cancer intrinsic subtypes by quantitative receptor expression

Charles M. Perou, Maggie Chon U Cheang, Aleix Prat, Angelo Di Leo, Lisa A Carey, Manuel Ruiz-Borrego, E Alba, Eva Carrasco, Rosalía Caballero
2015-06-05

Expression of HIF-1α and Markers of Angiogenesis Are Not Significantly Different in Triple Negative Breast Cancer Compared to Other Breast Cancer Molecular Subtypes: Implications for Future Therapy

Lamis Yehia
2015-07-01

Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial

George Fountzilas
2015-08-05

Clinical implications of the intrinsic molecular subtypes of breast cancer

Aranzazu Fernandez-Martinez, Ana Arance
2015-06-09

High vascular endothelial growth factor gene expression predicts poor outcome in patients with non-luminal A breast cancer
2014-06-16

A novel model for Ki67 assessment in breast cancer

Signe Borgquist
2013-10-07

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Patrick L. Fitzgibbons, Antonio C. Wolff, Societat Americana d'Oncologia Clínica, College of American Pathologists, Mitch Dowsett, Giuseppe Viale, Gail H. Vance, Edith Álvarez Pérez
2012

Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel

Mattheos Bobos, Urania Dafni, Athanasios Dimopoulos, George Fountzilas, Anna Batistatou, Vassiliki Kotoula, Savvas Papadopoulos, Helen Gogas, Dimitrios Bafaloukos, Despina Televantou, Konstantine T Kalogeras, Dimitrios Pectasides, Dimosthenis Skarlos, Angelos Koutras, Vassiliki Malamou-Mitsi, Sofia Chrisafi, Maria Sotiropoulou, Triantafyllia Koletsa
2012-11-12

The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Onco

George Fountzilas, Christos Christodoulou
2011-03-09

The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses' Health Study

Ying Liu, Graham Colditz, Rulla M Tamimi, Stuart J Schnitt, Laura Collins
2011-09-01

Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation

Dimosthenis Miliaras, Dimitra Repana, Christos Efstratiou
2011-12-21

Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial

Urania Dafni, Mattheos Bobos, Haralabos Kalofonos, Anastasia G Eleftheraki, Christos Markopoulos, Athanasios Dimopoulos, Anna Batistatou, Helen Gogas, Dimitrios Bafaloukos, Dimitrios Pectasides, Epaminontas Samantas, Pavlos Papakostas, Eleni Timotheadou, Evangelos Briasoulis, Charisios Karanikiotis
2010-02-05

Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up

Karin Jirström, Olle Stål
2010-02-09

Immunohistochemistry as an important tool in biomarkers detection and clinical practice
2010-05-11

Vascular endothelial growth factor receptor-2 in breast cancer
2010-06-01

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

Mitch Dowsett, Giuseppe Viale
2010-08-14

Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study

Graham Colditz, Rulla M Tamimi, Stuart J Schnitt, Shaheenah Dawood, Laura Collins
2009-06-03

Lymphangiogenic characteristics of triple negativity in node-negative breast cancer.
2009-06-23

Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer

Janne Lehtiö, Barbro K Linderholm
2008-01-13

Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer
2008-03-01

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

Maggie Chon U Cheang, Charles M. Perou
2008-05-08

Tumor angiogenesis
2007-03-13

Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis

Rabab A. Mohammed, Andrew R. Green, Ian Ellis, Stewart Martin
2007-01-01

Breast tumour angiogenesis

Stephen Fox, Daniele Generali, Adrian L Harris
2006-04-01

Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.

Athanasios Dimopoulos, Christos Markopoulos, George Fountzilas, Savvas Papadopoulos, Helen Gogas, Dimitrios Pectasides, Dimosthenis Skarlos, Ioannis Kostopoulos, Chrisoula D Scopa
2006-04-01

Vascular endothelial growth factor expression in the basal subtype of breast carcinoma
2006-09-01

Vascular endothelial growth factor signaling pathways: therapeutic perspective

Napoleone Ferrara
2006-09-01

Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis

Article - wd:Q90663359

Welcome to Inventaire

la biblioteca dels teus amics i comunitats

saber més